In conclusion, this subgroup analysis of the Japanese patients enrolled in the REACH-2 study showed a clinically meaningful benefit for ramucirumab, accompanied by a manageable safety profile, in Japanese patients with HCC who had previously received sorafenib and had baseline AFP ≥ 400 ng/mL. This evidence concerns the gene AFP and hepatocellular carcinoma.